Pfizer's Sutent succeeds in pancreatic neuroendocrine tumours
This article was originally published in Scrip
Executive Summary
Pfizer's multi-targeted anticancer Sutent (sunitinib) has improved progression-free survival (PFS) in a Phase III trial in patients with advanced pancreatic islet cell tumours (pancreatic neuroendocrine tumours).